{"id":"memantine-xr","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Constipation"},{"rate":"3-5%","effect":"Confusion"},{"rate":"2-5%","effect":"Hallucinations"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Memantine acts as a non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, reducing excitotoxicity caused by excessive glutamate. The extended-release formulation allows for once-daily dosing, improving patient compliance compared to immediate-release memantine. This mechanism is thought to slow cognitive decline in neurodegenerative conditions by protecting neurons from glutamate-mediated damage.","oneSentence":"Memantine-XR is an extended-release formulation of memantine, an uncompetitive NMDA receptor antagonist that blocks excessive glutamate signaling in the brain.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:39.136Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT02144584","phase":"EARLY_PHASE1","title":"Memantine for Enhanced Stroke Recovery","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Utah","startDate":"2014-01","conditions":"Ischemic Stroke, Upper Extremity Weakness","enrollment":20},{"nctId":"NCT05013892","phase":"PHASE2","title":"NTS-WBRT in Brain Metastases","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-02-08","conditions":"Brain Metastases","enrollment":41},{"nctId":"NCT02580305","phase":"PHASE2","title":"SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study","status":"COMPLETED","sponsor":"Suven Life Sciences Limited","startDate":"2015-09","conditions":"Alzheimer's Disease","enrollment":564},{"nctId":"NCT03709888","phase":"","title":"Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy","status":"COMPLETED","sponsor":"Saint John's Cancer Institute","startDate":"2016-07-09","conditions":"Chemotherapy-induced Peripheral Neuropathy","enrollment":20},{"nctId":"NCT02811627","phase":"EARLY_PHASE1","title":"Predicting Treatment Response to Memantine in Autism Using Magnetic Resonance Spectroscopy","status":"COMPLETED","sponsor":"University of Missouri-Columbia","startDate":"2016-06","conditions":"Autism Spectrum Disorder","enrollment":10},{"nctId":"NCT02079246","phase":"PHASE3","title":"Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2014-04-07","conditions":"Alzheimer's Disease","enrollment":1463},{"nctId":"NCT02234752","phase":"PHASE2","title":"Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia","status":"TERMINATED","sponsor":"Sheppard Pratt Health System","startDate":"2014-09","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":3},{"nctId":"NCT02353130","phase":"","title":"Cortical Metrics Assessment Outcome Measure Development in Autism With Memantine Treatment","status":"WITHDRAWN","sponsor":"University of North Carolina, Chapel Hill","startDate":"2015-07","conditions":"Autism Spectrum Disorders","enrollment":""},{"nctId":"NCT01999894","phase":"PHASE2","title":"Open-label Study of Safety and Tolerability of Memantine in Children With Autism","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2009-11","conditions":"Autism, Pediatric Autism","enrollment":102},{"nctId":"NCT00322153","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2005-06","conditions":"Dementia of the Alzheimer's Type","enrollment":677}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Namenda-XR","Memantine 20 mg"],"phase":"phase_3","status":"active","brandName":"Memantine-XR","genericName":"Memantine-XR","companyName":"University of North Carolina, Chapel Hill","companyId":"university-of-north-carolina-chapel-hill","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Memantine-XR is an extended-release formulation of memantine, an uncompetitive NMDA receptor antagonist that blocks excessive glutamate signaling in the brain. Used for Moderate to severe Alzheimer's disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}